224 related articles for article (PubMed ID: 33706339)
21. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period.
Middleton T; Schaff E; Fielding SL; Scahill M; Shannon C; Westheimer E; Wilkinson T; Winikoff B
Contraception; 2005 Nov; 72(5):328-32. PubMed ID: 16246656
[TBL] [Abstract][Full Text] [Related]
22. Pharmacy workers in Nepal can provide the correct information about using mifepristone and misoprostol to women seeking medication to induce abortion.
Tamang A; Puri M; Lama K; Shrestha P
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):104-15. PubMed ID: 25702074
[TBL] [Abstract][Full Text] [Related]
23. Simplified medical abortion screening: a demonstration project.
Raymond EG; Tan YL; Comendant R; Sagaidac I; Hodorogea S; Grant M; Sanhueza P; Van Pratt E; Gillespie G; Boraas C; Weaver MA; Platais I; Bousieguez M; Winikoff B
Contraception; 2018 Apr; 97(4):292-296. PubMed ID: 29170088
[TBL] [Abstract][Full Text] [Related]
24. Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol.
Guest J; Chien PF; Thomson MA; Kosseim ML
BJOG; 2007 Feb; 114(2):207-15. PubMed ID: 17305893
[TBL] [Abstract][Full Text] [Related]
25. Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of community pharmacists.
Zusman EZ; Munro S; Norman WV; Soon JA
BMJ Open; 2022 Oct; 12(10):e063370. PubMed ID: 36207038
[TBL] [Abstract][Full Text] [Related]
26. Medication abortion: Potential for improved patient access through pharmacies.
Raifman S; Orlando M; Rafie S; Grossman D
J Am Pharm Assoc (2003); 2018; 58(4):377-381. PubMed ID: 29752204
[TBL] [Abstract][Full Text] [Related]
27. "No Big Deal": A Qualitative Study of Pharmacists' Perspectives on Dispensing Mifepristone for Medication Abortion.
Kaller S; Ma M; Gurazada T; Baba CF; Rafie S; Raine-Bennett T; Averbach S; Chen M; Berry E; Meckstroth KR; Grossman D
Womens Health Issues; 2022; 32(6):571-577. PubMed ID: 35918240
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and acceptability of medical abortion provided through telemedicine.
Grossman D; Grindlay K; Buchacker T; Lane K; Blanchard K
Obstet Gynecol; 2011 Aug; 118(2 Pt 1):296-303. PubMed ID: 21775845
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion.
Schaff EA; Fielding SL; Westhoff C
Contraception; 2001 Aug; 64(2):81-5. PubMed ID: 11704083
[TBL] [Abstract][Full Text] [Related]
30. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial.
Winikoff B; Dzuba IG; Creinin MD; Crowden WA; Goldberg AB; Gonzales J; Howe M; Moskowitz J; Prine L; Shannon CS
Obstet Gynecol; 2008 Dec; 112(6):1303-1310. PubMed ID: 19037040
[TBL] [Abstract][Full Text] [Related]
31. Transcutaneous Electrical Nerve Stimulation to Reduce Pain With Medication Abortion: A Randomized Controlled Trial.
Goldman AR; Porsch L; Hintermeister A; Dragoman M
Obstet Gynecol; 2021 Jan; 137(1):100-107. PubMed ID: 33278292
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City.
Peña M; Dzuba IG; Smith PS; Mendoza LJ; Bousiéguez M; Martínez ML; Polanco RR; Villalón AE; Winikoff B
Int J Gynaecol Obstet; 2014 Oct; 127(1):82-5. PubMed ID: 24957534
[TBL] [Abstract][Full Text] [Related]
33. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City.
Sanhueza Smith P; Peña M; Dzuba IG; García Martinez ML; Aranguré Peraza AG; Bousiéguez M; Shochet T; Winikoff B
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):75-82. PubMed ID: 25702071
[TBL] [Abstract][Full Text] [Related]
34. Self-managed medication abortion outcomes: results from a prospective pilot study.
Moseson H; Jayaweera R; Raifman S; Keefe-Oates B; Filippa S; Motana R; Egwuatu I; Grosso B; Kristianingrum I; Nmezi S; Zurbriggen R; Gerdts C
Reprod Health; 2020 Oct; 17(1):164. PubMed ID: 33109230
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of mifepristone-buccal misoprostol for early medical abortion in an Australian clinical setting.
Goldstone P; Walker C; Hawtin K
Aust N Z J Obstet Gynaecol; 2017 Jun; 57(3):366-371. PubMed ID: 28303569
[TBL] [Abstract][Full Text] [Related]
36. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial.
Creinin MD; Schreiber CA; Bednarek P; Lintu H; Wagner MS; Meyn LA;
Obstet Gynecol; 2007 Apr; 109(4):885-94. PubMed ID: 17400850
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial.
Creinin MD; Schwartz JL; Pymar HC; Fink W
BJOG; 2001 May; 108(5):469-73. PubMed ID: 11368131
[TBL] [Abstract][Full Text] [Related]
38. Mifepristone followed by misoprostol or oxytocin for second-trimester abortion: a randomized controlled trial.
Elami-Suzin M; Freeman MD; Porat N; Rojansky N; Laufer N; Ben-Meir A
Obstet Gynecol; 2013 Oct; 122(4):815-820. PubMed ID: 24084539
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of telephone follow-up after medical abortion.
Perriera LK; Reeves MF; Chen BA; Hohmann HL; Hayes J; Creinin MD
Contraception; 2010 Feb; 81(2):143-9. PubMed ID: 20103453
[TBL] [Abstract][Full Text] [Related]
40. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days' gestation.
Hsia JK; Lohr PA; Taylor J; Creinin MD
Contraception; 2019 Sep; 100(3):178-181. PubMed ID: 31102629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
